Fusion Antibodies (LON:FAB) Shares Up 12.8% – Time to Buy?

Fusion Antibodies plc (LON:FAB) shares rose 12.8% during mid-day trading on Thursday . The company traded as high as GBX 7.95 ($0.10) and last traded at GBX 7.95 ($0.10). Approximately 981,343 shares traded hands during trading, a decline of 16% from the average daily volume of 1,166,639 shares. The stock had previously closed at GBX 7.05 ($0.09).

Fusion Antibodies Stock Performance

The company’s 50 day moving average price is GBX 5.48 and its 200-day moving average price is GBX 4.19. The stock has a market cap of £9.76 million, a P/E ratio of -255.85 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87.

Insiders Place Their Bets

In other Fusion Antibodies news, insider Adrian Kinkaid bought 83,728 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was purchased at an average cost of GBX 4 ($0.05) per share, with a total value of £3,349.12 ($4,160.40). 11.39% of the stock is currently owned by insiders.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.